Role of peroxisome proliferator-activated receptor-γ in the protection afforded by 15-deoxyΔ12,14 prostaglandin J 2 against the multiple organ failure caused by endotoxin

Critical Care Medicine

Volumn 32, Issue 3, 2004, Pages 826-831

  Collin, Marika ^a   Patel, Nimesh S A ^a   Dugo, Laura ^a   Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

15 deoxy 12,14 prostaglandin J2; GW9662; Lipopolysaccharide; Organ injury; Peroxisome proliferator activated receptor; Shock

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; ASPARTATE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; BILIRUBIN; DIMETHYL SULFOXIDE; ENDOTOXIN; GAMMA GLUTAMYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART INJURY; HEART RATE; KIDNEY DISEASE; LIVER INJURY; MALE; MULTIPLE ORGAN FAILURE; NEUROMUSCULAR DISEASE; NONHUMAN; PANCREAS INJURY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANILIDES; ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; LIPOPOLYSACCHARIDES; MALE; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; PROSTAGLANDIN D2; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 1542719543     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000114821.25573.E7     Document Type: Article

References (29)

1. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895
2. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20:649-688
3. Ricote M, Li AC, Willson TM, et al: The peroxisome proliferator activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82
4. Rossi A, Elia G, Santoro MG: Inhibition of nuclear factor kappa B by prostaglandin A1: An effect associated with heat shock transcription factor activation. Proc Natl Acad Sci 1997; 94:746-750
5. Straus DS, Glass CK: Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 2001; 21:185-210
6. Wayman NS, Hattori Y, McDonald MC, et al: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16:1027-1040
7. Cuzzocrea S, Ianaro A, Wayman NS, et al: The cyclopentenone prostaglandin 15-deoxy-delta(12, 14)-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003; 138:673-688
8. Wada K, Nakajima A, Blumberg RS: PPAR-gamma and inflammatory bowel disease: A new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001; 7:329-331
9. Cuzzocrea S, Chatterjee PK, Mazzon E, et al: Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 2002; 135:496-510
10. Leesnitzer LM, Parks DJ, Bledsoe RK, et al: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 28:6640-6650
11. Millar CG, Thiemermann C: Carboxy-PTIO, a scavenger of nitric oxide, selectively inhibits the increase in medullary perfusion and improves renal function in endotoxemia. Shock 2002; 18:64-68
12. Thiemermann C, Ruetten H, Wu CC, et al: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995; 116: 2845-2851
13. Baue AE: The multiple organ or system failure syndrome. In: Pathophysiology of Shock, Sepsis, and Organ Failure. Schlag G, Redl H (Eds). Berlin, Springer Verlag, 1993, pp 1004-1018
14. Hewett JA, Jean PA, Kunkel SL, et al: Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 1993; 265: G1011-G1015
15. Ruetten H, Thiemermann C: Effects of tyrphostins and genestein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase. Br J Pharmacol 1997; 122: 59-70
16. Ruetten H, Southan GJ, Abate A, et al: Attenuation of the multiple organ dysfunction caused by endotoxin by 1-amino-2-hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1996; 118:261-270
17. Fry DE, Pearlstein L, Fulton RL, et al: Multiple system organ failure: The role of uncontrolled infection. Arch Surg 1980; 115: 133-140
18. Baue AE, Durham R, Faist E: Systemic inflammatory response syndrome, multiple organ dysfunction syndrome, multiple organ failure: Are we winning the battle? Shock 1998; 10:79-89
19. Guyton K, Zingarelli B, Ashton S, et al: Peroxisome proliferator- activated receptor-gamma agonists modulate macrophage activation by Gram-negative and Gram-positive bacterial stimuli. Shock 2003; 20:56-62
20. Ti-Yue TL, Chen J, Bao W, et al: In vivo myocardial protection from ischaemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594
21. Hinz B, Brune K, Pahl A: 15-deoxy-delta(12, 14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. Biochem Biophys Res Commun 2003; 302:415-420
22. Aoun P, Watson DG, Simpkins JW: Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 2003; 472:65-71
23. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
24. McGowan JE Jr: Increasing threat of Gram-positive bacterial infections in the intensive care unit setting. Crit Care Med 2001; 29: N69-N74
25. Alpard SK, Zwischenberger JB, Tao W, et al: New clinically relevant sheep model of severe respiratory failure secondary to combined smoke inhalation/cutaneous flame burn injury. Crit Care Med 2000; 28:1469-1476
26. Murphey ED, Traber DL: Pretreatment with tumor necrosis factor-alpha attenuates arterial hypotension and mortality induced by endotoxin in pigs. Crit Care Med 2000; 28: 2015-2021
27. Murakami K, Bjertnaes LJ, Schmalstieg FC, et al: A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med 2002; 30:2083-2090
28. Booke M, Hinder F, McGuire R, et al: Selective inhibition of inducible nitric oxide synthase: Effects on hemodynamics and regional blood flow in healthy and septic sheep. Crit Care Med 1999; 27:162-167
29. Mehta S, Javeshghani D, Datta P, et al: Porcine endotoxemic shock is associated with increased expired nitric oxide. Crit Care Med 1999; 27:385-393